Magnesium clinical brief
Magnesium
Dossier liveAMetabolic
Evidence strength
High confidence
330 meta-analyses - 400 RCTs - 925 tracked studies
What it is for
Oral magnesium repletion for documented or suspected hypomagnesemia in adults
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HOMA-IR
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
Decrease
Grade A
Fasting insulin
Glycemic control
Decrease
Grade A
Top caution
Drug interaction
Baseline Mg correction is standard of care before initiating antiarrhythmic or QT-prolonging drugs; IV MgSO4 2g is first-line treatment for torsades de pointes
Evidence index
88
Authored product-registry confidence score
Meta-analyses
330
Pooled human evidence
RCTs
400
Randomized clinical trials
Tracked studies
925
Studies currently mapped to this dossier
Executive summary
Immediate brief
Magnesium is a Metabolic with its clearest current use in Oral magnesium repletion for documented or suspected hypomagnesemia in adults.
High confidence human evidence supports the brief, anchored by 925 tracked studies, 330 meta-analyses, 400 RCTs and the most reliable movement in HOMA-IR, HbA1c, Fasting insulin.
Baseline Mg correction is standard of care before initiating antiarrhythmic or QT-prolonging drugs; IV MgSO4 2g is first-line treatment for torsades de pointes Baseline Mg correction is standard of care before initiating antiarrhythmic or QT-prolonging drugs; IV MgSO4 2g is first-line treatment for torsades de pointes
Anchor decision
Oral magnesium repletion for documented or suspected hypomagnesemia in adults
Best current human use case
Confidence
High confidence
330 meta-analyses - 400 RCTs - 925 tracked studies
Read next
Drug interaction
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
BPregnancy - IV MgSO4 continuous infusion beyond 5-7 days
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Generalizability
ReviewMore than 60% of T2DM-specific RCTs contributing to glycemic MAs originate from China.
Generalizability
ReviewThe primary effect modifier across all endpoint clusters is baseline magnesium status.
Evidence scope
ReviewNormotensive subgroup analyses show SBP reduction of −0.9 mmHg (non-significant) while hypertensive subgroups show −3.1 to −4.2 mmHg.
Evidence scope
ReviewCRP and IL-6 reductions in MAs show I²>70% with primary signal from metabolic syndrome and T2DM subgroups.
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
No validated pairing data yet
No dossier-backed pairing evidence is currently mapped for Magnesium.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.